|
MYELODYSPLASTIC SYNDROME
|
|
0.010 |
GeneticVariation
|
BEFREE |
MDS was unrelated to the genotype and allele frequencies of c.516G>T SNP in CYP2B6.
|
20878158 |
2011 |
|
Miller Dieker syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
MDS was unrelated to the genotype and allele frequencies of c.516G>T SNP in CYP2B6.
|
20878158 |
2011 |
|
Tuberculosis
|
|
0.030 |
GeneticVariation
|
BEFREE |
A total of 418 patients with HIV-1 mono-infection, HIV-1 and Tuberculosis coinfection and symptomatic P. falciparum malaria were genotyped for the CYP2B6 c.516G>T SNP using Restriction Fragment Length Polymorphism (RFLP).
|
30818046 |
2019 |
|
Coinfection
|
|
0.010 |
GeneticVariation
|
BEFREE |
A total of 418 patients with HIV-1 mono-infection, HIV-1 and Tuberculosis coinfection and symptomatic P. falciparum malaria were genotyped for the CYP2B6 c.516G>T SNP using Restriction Fragment Length Polymorphism (RFLP).
|
30818046 |
2019 |
|
Malaria, Falciparum
|
|
0.010 |
GeneticVariation
|
BEFREE |
A total of 418 patients with HIV-1 mono-infection, HIV-1 and Tuberculosis coinfection and symptomatic P. falciparum malaria were genotyped for the CYP2B6 c.516G>T SNP using Restriction Fragment Length Polymorphism (RFLP).
|
30818046 |
2019 |
|
Schwartz-Jampel Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
CYP2B6 G516T and T983C single nucleotide polymorphisms (SNPs) were found to be associated with SJS/TEN susceptibility.
|
23774940 |
2013 |
|
Toxic Epidermal Necrolysis
|
|
0.010 |
GeneticVariation
|
BEFREE |
CYP2B6 G516T and T983C single nucleotide polymorphisms (SNPs) were found to be associated with SJS/TEN susceptibility.
|
23774940 |
2013 |
|
Absence of sensation
|
|
0.010 |
GeneticVariation
|
BEFREE |
From all the analysed changes, only polymorphism c.516G>T in the CYP2B6 gene and BMI affect the metabolism rate of propofol and may play an important role in the optimisation of propofol anaesthesia.
|
27826892 |
2017 |
|
Acute leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, we aimed to evaluate the association between genotype or allele of CYP2B6 516G>T SNP and acute leukemia and myelodysplastic syndrome (MDS).
|
20878158 |
2011 |
|
Tuberculosis
|
|
0.030 |
GeneticVariation
|
BEFREE |
HIV-infected patients with or without TB who had received combination antiretroviral therapy containing efavirenz (600 mg daily) for two weeks or greater were enrolled for determinations of CYP2B6 G516T polymorphism and plasma efavirenz concentrations with the use of polymerase-chain-reaction restriction fragment-length polymorphism and high-performance liquid chromatography, respectively.
|
24551111 |
2014 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
|
0.010 |
GeneticVariation
|
BEFREE |
In a North American, treated, adherent human immunodeficiency virus (HIV)-positive cohort (self-identified whites, n = 175; blacks, n = 218), we investigated whether CYP2B6 (516G>T, 983T>C), UGT2B7 (IVS1+985A>G, 802C>T), MDR1 3435C>T, chemokine (C-C motif) receptor 2 (CCR2) 190G>A, and CCR5 (-2459G>A, Δ32) polymorphisms influenced the time to achieve virologic success (TVLS).
|
21673041 |
2011 |
|
Systemic Scleroderma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Patients with systemic sclerosis (n = 10) or multiple sclerosis (n = 10), genotyped for the allelic variants of CYP2C9*2 and CYP2C9*3 and of the CYP2B6 G516T polymorphism, were treated with 50 mg cyclophosphamide/kg daily for 4 days.
|
28083951 |
2017 |
|
Multiple Sclerosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Patients with systemic sclerosis (n = 10) or multiple sclerosis (n = 10), genotyped for the allelic variants of CYP2C9*2 and CYP2C9*3 and of the CYP2B6 G516T polymorphism, were treated with 50 mg cyclophosphamide/kg daily for 4 days.
|
28083951 |
2017 |
|
CYP2B6 polymorphism
|
|
0.030 |
GeneticVariation
|
BEFREE |
Previous studies outside of the United Kingdom have shown associations between the CYP2B6 polymorphism G516T and increased toxicity.
|
19486190 |
2009 |
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |
|
Acute lymphocytic leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |
|
Adult Acute Lymphocytic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |
|
Leukemia, Myelocytic, Acute
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |
|
leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |
|
Childhood Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |
|
Congenital chromosomal disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |
|
Tuberculosis
|
|
0.030 |
GeneticVariation
|
BEFREE |
The G516T polymorphism in the CYP2B6 gene is a key predictor of the therapeutic response to treatment in TB patients.
|
25271170 |
2015 |
|
CYP2B6 polymorphism
|
|
0.030 |
GeneticVariation
|
BEFREE |
The aim of this study was to evaluate the clinical and economic impact of efavirenz (EFV) dose adjustment by monitoring plasma concentrations and pharmacogenetic analysis of the 516G>T CYP2B6 polymorphism.
|
24956253 |
2014 |
|
Neurologic Symptoms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The CYP2B6 G516T genotype was also associated with central nervous system symptoms at week 1 (P = 0.036).
|
15622315 |
2004 |
|
Asthenia
|
|
0.010 |
GeneticVariation
|
BEFREE |
The post-menopausal status was related to high levels of asthenia in docetaxel protocol whereas CYP2B6 polymorphism (rs3745274) was related to high levels in FAC protocol.
|
31056713 |
2020 |